• If you are wondering whether Ascendis Pharma shares still offer value after a strong run, it helps to step back and look at what the current price might be implying about the future.
• The stock recently closed at US$239.22, with returns of 4.9% over 7 days, 7.0% over 30 days, 12.2% year to date, 53.5% over 1 year, 117.5% over 3 years and 66.1% over 5 years, which may have changed how the market is thinking about its risk and potential.
• Recent news flow around Ascendis Pharma has focused on its progress as a pharmaceutical and biotech company and how that fits into longer term expectations for its pipeline and commercialisation efforts. This context helps explain why investors are watching the stock more closely and reassessing what they are willing to pay for its shares.
• On our checks, Ascendis Pharma has a valuation score of 2 out of 6. This reflects where it screens as undervalued across several metrics. Next we will walk through the usual valuation approaches before finishing with a way to look at value that can give you an even clearer picture.

Ascendis Pharma scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Ascendis Pharma Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes a series of future cash flow projections and discounts them back to today to estimate what the business might be worth right now.

For Ascendis Pharma, the latest twelve month free cash flow (FCF) is about €47.3m. Analysts have provided FCF estimates out to 2030, and Simply Wall St extends this into a 2 Stage Free Cash Flow to Equity model using projections and then extrapolations. The ten year projections, discounted back to today, range from about €382.8m in 2026 to roughly €1,165.4m in 2035, with a projected FCF figure of €1,355.0m in 2030 before discounting.

Putting all of those discounted cash flows together, the model arrives at an estimated intrinsic value of €808.79 per share. Compared with the recent share price of US$239.22, this suggests the stock is about 70.4% below the DCF estimate of fair value, which indicates a wide valuation gap based on this method alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ascendis Pharma is undervalued by 70.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Ascendis Pharma Price vs Sales

For companies where earnings are not the main focus yet, the P/S ratio is often a useful way to think about value, because it compares what you pay for each dollar of revenue rather than profit. The higher the expected growth and the lower the perceived risk, the more investors are usually willing to pay in terms of P/S, and the reverse is also true.

Ascendis Pharma currently trades on a P/S of 17.55x. That is above the Biotechs industry average P/S of 12.52x and close to the peer group average of 17.49x. Simply Wall St also calculates a proprietary Fair Ratio of 14.47x for Ascendis Pharma. This Fair Ratio is meant to reflect what a more customised P/S might look like after considering factors such as earnings growth outlook, profit margins, company size, risk profile and the broader industry context, rather than relying only on simple peer or industry comparisons.

Comparing the current 17.55x P/S to the Fair Ratio of 14.47x suggests Ascendis Pharma is trading above that customised benchmark, which indicates that the shares appear overvalued on this measure.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Ascendis Pharma Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. With Narratives, you set out your own story for Ascendis Pharma, link that story to specific forecasts for revenue, earnings and margins, and then see what fair value drops out and how it compares with the current price. This is all available within an easy tool on Simply Wall St’s Community page that millions of investors use. Narratives update automatically as new news or earnings arrive. You can, for example, see one investor building a cautious case around a fair value near US$193.36, while another builds a more optimistic case closer to US$306.97 or even US$319. You can then decide for yourself which version of the Ascendis Pharma story you find more convincing.

Do you think there's more to the story for Ascendis Pharma? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.